Publications and Presentations Featuring Spero Therapeutics Drug Candidates and Research

Browse through key publications and presentations that have discussed our drug candidates and our work involving the treatment of bacterial infections.

Presentation Categories

Oral 6
Poster 86
Written 13
Select All

Antimicrobial activity evaluation of tebipenem (SPR859), an orally available carbapenem, against a global set of Enterobacteriaceae, including a challenge set of organisms

May 24, 2019

Antimicrobial Agents and Chemotherapy, AAC.02618-18, DOI: 10.1128/AAC.02618-18 S.J. Ryan Arends, Paul R. Rhomberg, Nicole Cotroneo, Aileen Rubio, Robert K. Flamm and Rodrigo E. Mendes

Pharmacodynamics of Ertapenem

April 16, 2019

Phase 3 Dose Selection for Tebipenem

April 16, 2019

Activity of tebipenem, an oral carbapenem, against multidrug-resistant urinary tract infection-causing pathogens with characterized resistance mechanisms collected in Europe and the United States in 2016

April 16, 2019

Escherichia coli from urinary tract infections in Europe in 2017 are increasingly multidrug-resistant to oral antibiotics in an era of co-resistance to extended-spectrum beta-lactamases

April 15, 2019

Pages: 12345678910111213141516171819202122232425

Publications and Presentations Featuring Spero Therapeutics Drug Candidates and Research

Presentation Categories

Presentation Tags